Genetic testing, a critical medical procedure, identifies alterations in genes, chromosomes, or proteins to confirm or rule out genetic conditions and assess an individual's risk of developing or passing on such disorders. This market is booming, with the global genetic testing market projected to grow from $8.84 billion in 2023 to an estimated $64.73 billion by 2033, driven by technological advancements, increased awareness, and expanding applications. The U.S. genomics market alone is set to reach around $43.81 billion by 2032, growing at a CAGR of 19.4%.
Thus, it could be opportune to invest in fundamentally sound biotech stocks. Let’s determine whether investors should place their bets on Veracyte, Inc. (VCYT) in genomic diagnostics.
